WASHINGTON, DC – The Energy and Commerce Subcommittee on Health today will convene a hearing with federal and state officials to discuss the implementation and regulation of the health exchanges and Medicaid expansion established in the Patient Protection and Affordable Care Act. Governors, members of Congress, and state officials have sent numerous letters requesting this basic information. While informal guidance and some proposed or final rules have been issued, unanswered questions or incomplete answers leave states wondering:
WASHINGTON, DC – The Energy and Commerce Subcommittee on Communications and Technology, chaired by Rep.
WASHINGTON, DC – Communications and Technology Subcommittee Chairman Greg Walden (R-OR) today issued the following statement on the Federal Communications Commission’s newly created “Technology Transitions Policy Task Force”:
Grassley, Upton Seek Details of Potential Conflicts of Interest for Health Care Firms Involved in Implementation of Health LawDecember 10, 2012 | Press Release
WASHINGTON, DC –Rep. Fred Upton and Sen. Chuck Grassley today asked two health care companies for information on whether they would limit any potential conflicts of interest presented by their involvement in implementing and potentially providing services under the health care reform law.
WASHINGTON, DC – The House Energy and Commerce Committee today announced its schedule for the week of December 10, 2012. The committee will hold hearings to exercise oversight over new spectrum auction authority Congress gave the FCC this year and implementation of the health care law’s exchanges and Medicaid expansion.
WASHINGTON, DC –House Energy and Commerce Committee leaders sent a letter to the International Academy of Compounding Pharmacists seeking information on the role of this industry association in assisting compounding pharmacies in their interactions with federal and state authorities. A bipartisan group of committee leaders wrote, “Allegations that your association may have encouraged compounding pharmacists to attempt to impede FDA from evaluating the efficacy and safety of their products, if true, raise serious concerns about your actions.”